Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Lilly to Participate in Guggenheim Biopharma Strategy Series

06/14/2021 | 10:01am EDT

INDIANAPOLIS, June 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific and Medical Officer and President of Lilly Research Laboratories, will participate in a virtual fireside chat at 11:00 a.m., Eastern Time.

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

About Eli Lilly and Company  
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/news. F-LLY

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company)

 

Refer to: 

Molly McCully; mccully_molly@lilly.com; 317-478-5423 (Media)


Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (Investors)     

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-to-participate-in-guggenheim-biopharma-strategy-series-301311034.html

SOURCE Eli Lilly and Company


ę PRNewswire 2021
All news about ELI LILLY AND COMPANY
03:01pELI LILLY AND : Lilly releases donanemab data that demonstrated relationship bet..
PR
10:57aELI LILLY AND : Incyte Get Expanded Emergency Use Approval for Baricitinib as Mo..
MT
10:02aEli Lilly, Kumquat Biosciences Form Cancer Collaboration
DJ
09:27aELI LILLY AND : FDA broadens existing emergency use of Lilly and Incyte's barici..
PR
09:03aELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules for Tumor Immunit..
MT
08:04aLilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monot..
DJ
07:49aELI LILLY AND : Unit, Kumquat Biosciences to Develop Molecules to Invoke Tumor I..
MT
06:46aELI LILLY AND : Lilly and Kumquat Biosciences Announce Collaboration to Discover..
PR
07/23ELI LILLY AND : (LLY) sees Significant Insider Selling Continuing
MT
07/23A Guiding Light For The Research Safe Harbor And "Research Tools"?
AQ
More news